Etiqueta: stem cells

After reporting strong fourth-quarter growth, Genzyme announces an optimistic economic forecast.

The umbilical cord blood stem cell preservation company, Cord Blood America, announces a new campaign to engage the attention and interest of clients, investors and the general public through the new platform of social networking technology.

The California based biotechnology company ISCO receives the first $1 million tranche of private equity funding.

Anthrogenesis Corporation, a division of Celgene, is awarded yet another U.S. patent for inventions related to methods of deriving adult stem cells from human placentas.

A U.S. doctor has been invited to visit China as part of a fact-finding mission on the current state of stem cell therapies that are only available outside of the United States.

The U.S. Food and Drug Administration has granted marketing approval for Mozobil, Genzyme’s patented drug which stimulates the mobilization of autologous adult stem cells, now available for the treatment of non-Hodgkin’s lymphoma and multiple myeloma.

A new publication issued by the Vatican has high praise for adult stem cell research and therapies, but not for embryonic stem cell research.

While the treatment of people with stem cells is still somewhat of a controversial topic, veterinary applications of stem cell therapy are enjoying unbridled enthusiasm and success.

Researchers move one step closer to understanding the origin of prostate cancer cells.